trial

Cognitive Enhancement Therapy for Early-Stage Schizophrenia

NCTId NCT00167362
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 67 (actual)
Sponsored by Beth Israel Deaconess Medical Center
Primary completion 2009-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
67 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2001-08
Primary completion
2009-08
Eligibility
ALL · 16 Years · 51 Years

Interventions & indications

Drugs
Cognitive Enhancement Therapy (CET)Enriched supportive therapy (EST)

Sponsors

Beth Israel Deaconess Medical CenterLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

2
Matcheri S. Keshavan, MDPrincipal Investigator
Gerard E Hogarty, MSWPrincipal Investigator

Sites

1 total
Pittsburgh, United States

Linked catalysts

1
Cognitive Enhancement Therapy for Early-Stage Schizophrenia — primary completion2009-08

Facts & assertions

4 sourced
Enrollment
67
Phase
PHASE3
Primary Completion Date
2009-08
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive Enhancement Therapy (CET)
drug
Enriched supportive therapy (EST)
drug
lead_sponsor
Beth Israel Deaconess Medical Center
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Matcheri S. Keshavan, MD
person
Gerard E Hogarty, MSW
person